Cencora, Inc. · NYSE:COR
Cencora — AmerisourceBergen — Q2 FY2020 Earnings Presentation
13 slides from Cencora's earnings presentation, May 7, 2020
Slide 1: Q2 FY2020 Financial Results
Q2 FY2020 Financial Results May 7, 2020
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as "expect," "likely," "ou
Slide 3: AmerisourceBergen is united in our responsibility to create healthier futures
AmerisourceBergen is united in our responsibility to create healthier futures. AmerisourceBergen drives innovative partnerships with global manufacturers, providers and pharmacies to improve product access and efficiency throughout the healthcare supply chain. 3
Slide 4: Q2 FY2020 Financial Results: Overview
Q2 FY2020 Financial Results: Overview • Protecting and supporting our associates • Comprehensive business continuity plans COVID-19 Response • Continuous communication with manufacturers and providers • Internal task force working to protect associate health and wellbeing while ensuring patient acce
Slide 5: Q2 FY2020 Financial Results
Q2 FY2020 Financial Results Adjusted GAAP (non-GAAP)1 Revenue $47.4B $47.4B % Change (Year-over-Year) 9.5% 9.5% Gross Profit $1.4B $1.4B % Change (2.6)% 7.5% Operating Expenses $1,079M $745M % Change (21.7)% 6.2% Operating Income $310M $672M % Change 550.7% 8.9% Interest Expense, Net $34M $34M % Cha
Slide 6: Pharmaceutical Distribution Services Segment
Q2 FY2020 Financial Results: Pharmaceutical Distribution Services Segment Q2 FY2020 Q2 FY2019 Revenue $45.6B $41.7B Operating Income $563.1M $517.0M Percentages of Revenue Gross Profit 2.32% 2.38% Operating Expenses 1.08% 1.14% Operating Income 1.24% 1.24% ▪ Revenue increase primarily due to organic
Slide 7: Other – Global Commercialization Services & Animal Health
Q2 FY2020 Financial Results: Other – Global Commercialization Services & Animal Health Q2 FY2020 Q2 FY2019 Revenue $1.9B $1.7B Operating Income $108.3M $99.9M Percentages of Revenue Gross Profit 19.15% 19.60% Operating Expenses 13.38% 13.60% Operating Income 5.77% 6.00% ▪ Other includes MWI, World C
Slide 8: Differentiated and positioned for growth
Differentiated and positioned for growth Customer Base Innovative Services & • Key anchor customers Solutions • Fast growing • Customer-focused offerings • U.S. Pharmaceutical focus serving manufacturers and provider customers Leadership in Specialty Successful Corporate Distribution & Services Stew
Slide 9: FY20 Financial Guidance
FY20 Financial Guidance Expectations on an Adjusted (non-GAAP) Basis Low- to mid-single digit Revenue percent growth Diluted Earnings Per Share $7.35 to $7.65 Low-single digit percent Operating Expense growth Low- to mid-single digit Operating Income percent growth Pharmaceutical Distribution Servic
Slide 10: Appendix
Appendix N) AmerisourceBergen’
Slide 11: Appendix
Appendix Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the exhibit to the Company’s most recent Current Report on Form 8-K furnished under Item 2.02. 11
Slide 12: Appendix
Appendix Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the exhibit to the Company’s most recent Current Report on Form 8-K furnished under Item 2.02. 12
Slide 13: AmerisourceBergen: Where knowledge, reach and partnership shape healthcare delivery
N) AmerisourceBergen’ Where knowledge, reach and partnership shape healthcare delivery.